- 7-Day Challenge integrates wearable technology and social media to track daily activities of people with MS, allowing valuable personal insights to enable change
- Novartis is collaborating with Tictrac, a personal analytics company, to empower people with MS via a personal tracking system, to learn more about their lives
- There is a high interest amongst the MS community to learn about their lifestyles in order to make adjustments that can help to improve their daily lives with MS
Basel, May 28, 2014 - In support of World MS Day, Novartis announced today the launch of the 7-Day Challenge to Live Like You for people with MS. The 7-Day Challenge to Live Like You, one of the first integrations of emerging technological trends by a pharmaceutical company, is simple: using wearable technology or accessing personal online systems that people use on a daily basis, including calendars, social media channels and fitness trackers, people with MS are invited to track their activities for seven days and gain valuable insights into what works best for their lifestyle. The 7-Day Challenge to Live Like You, which can be accessed via http://7daychallenge.tictrac.com, addresses the growing desire amongst the MS community to gather personalized information that will allow them to make decisions on how they can manage their lives with MS.
World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS and its impact on approximately 2.3 million people with MS around the world. This year's World MS Day campaign focuses on 'access'. Importantly, the topic of access spans beyond access to treatment in MS. Increasingly, there is a need for access to relevant and personalized online information that allows people to utilize available tools in order to make adjustments that can help them to manage their MS in a way that best suits their lifestyle.
"Novartis is a proud supporter of World MS Day, and we recognize the value of providing access to personalized information for the MS community," said David Epstein, Division Head, Novartis Pharmaceuticals. "As part of our commitment to providing innovative solutions that go beyond treatments, we are delighted to announce the launch of the 7-Day Challenge to Live Like You, which will empower the MS community to gain valuable insights about themselves and their MS."
The 7-Day Challenge to Live Like You is a collaboration between Novartis and Tictrac, an innovative technology company with expertise in tracking user data and turning the data into unique perceptions (e.g. 'you're more active after a good night's sleep') that can help people with MS better understand their lifestyle in order to make small changes based on their new insights. Alongside the 7-Day Challenge to Live Like You, Novartis also recently launched Living Like You (www.livinglikeyou.com), an online resource community that features personal content for the MS community.
For people with MS, personalized information and tracking is essential because it can help with symptom management and take the guesswork out of what is and isn't working - and allow small changes that could help in achieving meaningful results. The tracking does not need to stop after the seven days are up; the 7-Day Challenge to Live Like You online tracking program will still be available to the MS community, to empower people with MS to continue to gain valuable insights about themselves and how to better manage their life with this debilitating disease.
About Living Like You
The Novartis-supported Living Like You (www.livinglikeyou.com) is an online resource community that features magazine-style content detailing the journey through the realities of life with MS by offering insights from people who live with the disease. Providing access to relevant information online is important as people with MS are up to three times more likely to be online compared to people with other diseases; in fact, MS is mentioned online every 13 seconds.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) that disrupts the normal functioning of the brain, optic nerve and spinal cord. The evolution of MS results in an increasing loss of both physical (e.g. difficulty with walking) and cognitive (e.g. problems with mental tasks or memory) function. This has a substantial negative impact on the approximately 2.3 million people worldwide affected by MS, a disease that begins in early adulthood, most often between the ages of 20 and 40.
The loss of physical and cognitive function is driven by two main types of damage that both contribute to widespread loss of neurons (nerve cells in the brain and spinal cord that transmit impulses): discrete inflammatory lesions, focal damage, in the brain that can clinically manifest as relapses; and ongoing, more diffuse damage that starts early in the disease and causes the progressive loss of brain tissue, including neurons, and over time is associated with both physical and cognitive problems-.
About Novartis in Multiple Sclerosis
Novartis is committed to the research and development of new treatment options to offer the right treatment to the right patient at the right time, to meet patients' needs at every stage of disease with innovative and targeted drugs.
In addition to its ongoing development program for Gilenya in primary progressive MS (PPMS), pediatric MS and chronic inflammatory demyelinating polyneuropathy (CIPD), the Novartis MS portfolio includes Extavia® (interferon beta-1b for subcutaneous injection). Investigational compounds include BAF312 (siponimod), which is currently in Phase III clinical development and being developed as the first oral therapy for secondary progressive MS (SPMS), and VAY736, an anti-B-cell compound for MS that is currently being investigated in proof of concept studies. Novartis is also exploring the IL-17 pathway in MS.
The foregoing release contains forward-looking statements that can be identified by words such as "launches," "can," "growing," "will," "commitment," "launch," "committed," "ongoing," "investigational," "exploring," or similar terms, or by express or implied discussions regarding potential new indications or labeling for Gilenya, potential future marketing submissions or approvals for the investigational compounds in the Novartis MS portfolio, or regarding potential future revenues from any of the products and investigational compounds in the Novartis MS portfolio. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Gilenya will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that any of the investigational compounds in the Novartis MS portfolio will be submitted or approved for sale in any market, or at any particular time. Nor can there be any guarantee that any of the products and investigational compounds in the Novartis MS portfolio will be commercially successful in the future. In particular, management's expectations regarding these products could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.
 http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1. Accessed May 2014.
 Data on file. Novartis Pharmaceuticals. 'Multiple Sclerosis on the Social Web' social web audit.
 http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed May 2014.
 http://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed May 2014.
 http://emsp.org/multiple-sclerosis/ms-fact-sheet. Accessed May 2014.
 Filippi M et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 Apr;11(4):349-60.
 Kutzelnigg A et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 Nov;128(Pt 11):2705-12.
 Sormani MP, Arnold DL & De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43-9.
# # #
Novartis Media Relations
|Central media line : +41 61 324 2200|
| Eric Althoff |
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
| Katrina Lucking |
Novartis Global Pharma Communications
+41 61 324 12 18 (direct)
+41 79 171 8267 (mobile)
Novartis Investor Relations
|Central phone:||+41 61 324 7944|
|Samir Shah||+41 61 324 7944||North America:|
|Pierre-Michel Bringer||+41 61 324 1065||Stephen Rubino||+1 862 778 8301|
|Thomas Hungerbuehler||+41 61 324 8425||Susan Donofrio||+1 862 778 9257|
|Isabella Zinck||+41 61 324 7188|
|e-mail: firstname.lastname@example.org||e-mail: email@example.com|